Literature DB >> 12192622

Association between presenilin-1 Glu318Gly mutation and familial Alzheimer's disease in the Australian population.

K Taddei1, C Fisher, S M Laws, G Martins, A Paton, R M Clarnette, C Chung, W S Brooks, J Hallmayer, J Miklossy, N Relkin, P H St George-Hyslop, S E Gandy, R N Martins.   

Abstract

Mutations in the presenilin-1 (PS-1) gene on chromosome 14 account for the majority of early-onset familial Alzheimer's disease (FAD) cases. To date, more than 90 mutations have been identified and, while most of these mutations are completely penetrant, the Glu318Gly mutation has been suggested to be partially penetrant. These findings indicate that it may play a similar role to apolipoprotein E (APOE)-epsilon4 by acting as a genetic risk factor for AD. In the current study, a total of 682 subjects were tested to assess the frequency of the Glu318Gly mutation in AD in the Australian population. The Glu318Gly mutation was identified in six sporadic late-onset AD patients, four FAD patients (unrelated) and in nine control subjects. The frequency of this mutation was highest in the familial AD group (8.7%) and lowest in control subjects (2.2%). When the mutation frequencies were compared, we found a statistically significant difference between the latter two groups (Fisher's exact test, P < 0.05). The genotype frequency of the Glu318Gly mutation in all AD cases and controls in the Australian population was 2.8%. This frequency is comparable to that observed for the Dutch population (3.2%), but not for the Finnish population (6.8% and 6.0%) or the Spanish population (5.3%). These findings show that the frequency of the Glu318Gly mutation is increased in FAD patients, suggesting a potential role as a genetic risk factor contributing to the pathogenesis of familial AD.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12192622     DOI: 10.1038/sj.mp.4001072

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  6 in total

1.  The PSEN1, p.E318G variant increases the risk of Alzheimer's disease in APOE-ε4 carriers.

Authors:  Bruno A Benitez; Celeste M Karch; Yefei Cai; Sheng Chih Jin; Breanna Cooper; David Carrell; Sarah Bertelsen; Lori Chibnik; Julie A Schneider; David A Bennett; Anne M Fagan; David Holtzman; John C Morris; Alison M Goate; Carlos Cruchaga
Journal:  PLoS Genet       Date:  2013-08-22       Impact factor: 5.917

2.  Late onset familial Alzheimer's disease: novel presenilin 2 mutation and PS1 E318G polymorphism.

Authors:  Livia Bernardi; Carmine Tomaino; Maria Anfossi; Maura Gallo; Silvana Geracitano; Gianfranco Puccio; Rosanna Colao; Francesca Frangipane; Maria Mirabelli; Nicoletta Smirne; Raffaele Giovanni Maletta; Amalia C Bruni
Journal:  J Neurol       Date:  2008-03-25       Impact factor: 4.849

Review 3.  Alzheimer's disease genetics: from the bench to the clinic.

Authors:  Celeste M Karch; Carlos Cruchaga; Alison M Goate
Journal:  Neuron       Date:  2014-07-02       Impact factor: 17.173

4.  Atypical Huntington's disease with the clinical presentation of behavioural variant of frontotemporal dementia.

Authors:  Stanislav Sutovsky; Tomas Smolek; Irina Alafuzoff; Andrej Blaho; Vojtech Parrak; Peter Turcani; Michal Palkovic; Robert Petrovic; Michal Novak; Norbert Zilka
Journal:  J Neural Transm (Vienna)       Date:  2016-06-10       Impact factor: 3.575

5.  Genetic studies in Alzheimer's disease.

Authors:  Ya-Ping Tang; Elliot S Gershon
Journal:  Dialogues Clin Neurosci       Date:  2003-03       Impact factor: 5.986

6.  Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer's disease families.

Authors:  Carlos Cruchaga; Gabe Haller; Sumitra Chakraverty; Kevin Mayo; Francesco L M Vallania; Robi D Mitra; Kelley Faber; Jennifer Williamson; Tom Bird; Ramon Diaz-Arrastia; Tatiana M Foroud; Bradley F Boeve; Neill R Graff-Radford; Pamela St Jean; Michael Lawson; Margaret G Ehm; Richard Mayeux; Alison M Goate
Journal:  PLoS One       Date:  2012-02-01       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.